 The treatment phase consisted of two parts of 24 weeks for a total of 48 weeks. The first part weeks 1 to 24 consisted of treatment with either FOLFOX4, FOLFOX4 in combination with bevacizumab, or XELOX in combination with bevacizumab. The second part weeks 25 to 48 consisted of single-agent bevacizumab for patients randomized to either bevacizumab-containing arm, but was only an observation period for patients assigned to the FOLFOX4-alone arm. 